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In this issue: Cardiac Markers. The World is Changing – Are We Ready?
ST2 and galectin-3: ready for prime time?
Wouter C. Meijers, A. Rogier van der Velde, Rudolf A. de Boer
University Medical Center Groningen, University of Groningen, The Netherlands
A R T I C L E  I N F O A B S T R A C T
ST2 and galectin-3 are emerging biomarkers in the 
field of heart failure and have been extensively stud-
ied, and that whether they provide additional prog-
nostic value on top of the clinical models and the gold 
standard in HF, (NT-pro)BNP. Our aim was to provide a 
comprehensive review of these emerging HF-related 
biomarkers in chronic, acute and incident heart fail-
ure. Regardless of the type of heart failure, both bio-
markers seem to have an additional effect on top 
of the clinical model including natriuretic peptides. 
Strategies that combine multiple biomarkers may ul-
timately prove to be beneficial in the guidance of HF 
therapy in the future. However, additional prognostic 
value appears to be limited, and what we need is to 
prospectively test the consistent observations, which 
then might lead to the implementation of ST2 and 
galectin-3 in heart failure algorithms. 
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1. INTRODUCTION
Heart failure (HF) is a major public health prob-
lem and affects more than 25 million patients 
worldwide. The lifetime risk for development of 
heart failure (HF) is more than 20% for people at 
the age of 40 and it is a major cause of morbidity 
and mortality in the western world (1). Although 
considerable improvements have been made in 
HF therapy, 5-year mortality rates remain unac-
ceptably high, exceeding 50% (2). We can expect 
that, due to an aging population, the prevalence 
of HF will rise, at an alarming rate (3). 
Therefore, better insight in the pathophysi-
ological mechanisms that cause HF is needed. 
Biomarkers that reflect such mechanisms may 
assist in risk stratification and may help to create 
treatment strategies for the individual patient. 
Biomarkers may aid in the diagnosis of heart 
failure, or may be used to risk stratify patients, 
or to guide treatment. As such, numerous bio-
markers have entered the heart failure arena. 
The vast number of biomarker articles has been 
referred to as a “biomarker tsunami” (4), but 
most biomarkers are still under investigation as 
therapeutic consequence and their role in dis-
ease management remains unclear at this stage.
The biomarker that is considered the gold stan-
dard, and is mentioned as such in HF guidelines, 
is B-type natriuretic peptide (BNP, or its stable 
precursor, NT-proBNP); this biomarker has es-
tablished itself to be useful in diagnosis, prog-
nosis, and disease management (5). In acutely 
decompensated patients with high volume 
load, the cardiac wall endures stress resulting in 
highly elevated BNP levels, which is loading de-
pendent, and therefore will drop after unload-
ing (6). However, BNP has its drawbacks, and is 
influenced by the “loading status” of the patient 
during presentation, but also by renal function, 
and obesity (7-9).
As mentioned by the 2013 American College of 
Cardiology/American Heart Association guideline 
for the management of heart failure, both galec-
tin-3 and ST2 are emerging biomarkers that are 
not only predictive for hospitalization and death 
in patients with HF, but also add additional prog-
nostic value over natriuretic peptides (10). 
ST2 and galectin-3:  
basic biology and functions
Suppression of tumorigenicity 2 (ST2), also 
known as IL1-RL1, is a member of the Toll-like/
IL-1 receptor superfamily. As member of this 
family, ST2 consists of a common intracellular 
domain, the Toll/Interleukin-1 receptor (TIR). 
The gene for ST2 is located on chromosome 
2q12 and is conserved across species. Four iso-
forms of ST2 exist namely, sST2, ST2L, ST2V and 
ST2LV. The soluble (sST2) and the transmem-
brane (ST2L) are mostly studied in HF research. 
sST2 lacks the transmembrane and cytoplas-
mic domains and includes a nine amino-acid 
C-terminal sequence. ST2 is upregulated by car-
diomyocytes and cardiac fibroblasts when me-
chanical stress is imposed, for instance stretch. 
The ligand for ST2 is IL-33, another of member of 
the IL-1 interleukin family. When bound to IL33, 
ST2L confers an inhibitory effect on the Th2-
dependent inflammatory response. Soluble ST2 
can bind IL33, and it is hypothesized that sST2 
works as a decoy receptor to IL-33 (11) (Figure 
1A). Nowadays, it is thought that IL-33 signalling 
through ST2L provides a cardioprotective phe-
notype to protect the heart from excess stress, 
and that sST2 may neutralize this protective ef-
fect (12). In this article, we will use ST2 invari-
ably, regardless if we refer to sST2 or ST2L. 
Galectin-3 is encoded by a single gene, LGALS3, 
which is located on chromosome 14. It consists 
of two domains, namely an atypical N-terminal 
domain and a C-terminal carbohydrate-recog-
nition domain (CRD). During differentiation of 
monocytes into macrophages galectin-3 is re-
leased and is involved in many processes dur-
ing the acute inflammatory response such as 
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A. sST2 in the extracellular environment might bind free IL-33, thereby effectively decreasing the concentration of IL-33 
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neutrophil activation and adhesion, chemoat-
traction of monocytes, opsonization of apop-
totic neutrophils and activation of mast cells. 
Galectin-3 has been identified as a causal factor 
in the development of fibrosis of the heart (and 
other organs). The potential roles of galectin-3 
in HF are displayed in Figure 1B (13,14). 
Established risk factors, such as New York Heart 
Association (NYHA) functional class, medication 
use, routine laboratory values, and left ventric-
ular ejection fraction (LVEF), do not fully explain 
the mortality risk of patients with chronic HF 
and do not estimate the prognosis of individu-
als (15,16). Both ST2 and galectin-3 reflect tis-
sue damage, independent of cardiac loading 
conditions. As such, they may supplement the 
currently used biomarkers. We herewith discuss 
articles describing these emerging HF-related 
biomarkers in chronic, acute and incident heart 
failure. 
2. CHRONIC HEART FAILURE
2.1. ST2
ST2 can reliably be measured with three differ-
ent assays. The MBL assay, the R&D assay and 
the Presage assay. The latter assay is FDA-cleared 
and CE marked, while the other two methods 
are research assays. These three methods are 
not directly comparable and it is important to 
be informed which method was used when in-
terpreting the results (17). Dieplinger et al. re-
ported that only the Presage ST2 assay meets 
the needs of quality specification of laboratory 
medicine (18). 
We can only discuss a subset of the published 
studies, and there are many more. We refer to 
recent excellent review articles that summa-
rize all the available evidence for ST2 (19-21). 
Currently, we lack a meta-analysis that would 
help to compile the aggregate evidence. We dis-
cuss a few of the most interesting articles.
One of the first published reports on ST2 and 
chronic HF was published by Pascual-Figal et al. 
(22). They demonstrated that ST2 could predict 
sudden cardiac death in ambulatory patients 
(N=99) with mild to moderate HF and systolic 
dysfunction. >70% of sudden cardiac death oc-
curred in patients with both elevated ST2 and 
NT-proBNP levels compared to 4% when both 
markers were low (13). 
Daniels et al. (23) reported in a larger cohort of 
HF patients which were referred for echocardio-
gram (N=588) that heart rate, current diuretic 
use, estimated creatinine clearance, the pres-
ence/absence of right ventricular hypokinesia, 
and mitral valve E wave velocity were indepen-
dently associated with ST2 levels. In addition to 
association analyses, they also observed that 
multivariate adjusted ST2 levels were signifi-
cantly predictive for all-cause mortality after one 
year. 
In a much larger study in 2011, Ky et al. (24) re-
ported of 1141 chronic HF patients. The Penn 
Heart Failure Study (PHFS) investigators con-
cluded that ST2 is strongly associated with HF 
severity. Patients with elevated levels of cir-
culating ST2 had a markedly increased risk of 
death or heart transplantation. In the assess-
ment of individual patient risk, ST2 performed 
equally well compared to the established bio-
marker NT-proBNP. 
The relationship of ST2 and renal function was 
studied in the Barcelona study (25). This study 
included 891 patients, and demonstrated that 
the prognostic value of ST2 was not influenced 
by renal function. This finding suggests that ST2 
may be advocated as a preferable biomarker in 
patients with renal insufficiency, a co-morbidity 
that is very common in HF and is among the 
best predictors of adverse outcomes. 
Functional capacity and long-term clinical out-
comes in ambulatory patients was studied by 
Felker et al. (26) in a Controlled Trial Investigating 
eJIFCC2016Vol27No3pp238-252
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Outcomes of Exercise Training (HF-ACTION) study. 
ST2 was measured in a sub-set of 910 patients 
and was associated with cardiovascular death 
and HF hospitalization even after comprehen-
sive covariate adjustment. Combining ST2 with 
NT-proBNP rendered the strongest predictive 
value (Figure 2A). However, the addition of ST2 
to the model did not result in significant reclas-
sification in this study. 
Another large trial, the Controlled Rosuvastatin 
Multinational Trial in Heart Failure (CORONA) 
study, comprising of 1449 patients, demon-
strated the association between ST2 and cause-
specific outcomes (27). Next to the primary end-
point (a composite of cardiovascular (CV) death, 
non-fatal myocardial infarction, and stroke), the 
authors also studied the association of ST2 with 
worsening HF. ST2 indeed was associated with 
the primary endpoint, but was no longer associ-
ated after full adjustment including NT-proBNP 
and CRP, however ST2 remained associated with 
death due to worsening HF, hospitalization due 
to worsening HF, and hospitalization due to any 
CV cause, also after full adjustments. The latter 
could suggest that the ST2 pathway, in addition 
to its value in risk stratification of death is also rel-
evant in determining disease progression in HF. 
A recent study with a long follow-up of nearly 4 
years by Gruson et al. showed in 137 HF patients 
with reduced LVEF that ST2 predicted long-term 
CV death, even stronger then NT-proBNP (28). 
2.2. Galectin-3
Several commercially available assays can mea-
sure galectin-3 plasma or serum levels (29). 
Manually, galectin-3 can be measured with the 
BG Medicine assay (30) and the R&D assay (31). 
But several automated assays are available to 
measure galectin-3, including the ARCHITECT 
assay (32), the Vidas assay (33), and an Alere 
assay. The possibility to measure galectin-3 
values on an automated platform allows for a 
quick, easy and reliable measurement of galec-
tin-3 levels. By far, most published data have 
been measured with the BGM assay, however 
the ARCHITECT and VIDAS assays use the same 
antibodies and are calibrated against the BGM 
assay, making reported values comparable 
throughout the literature. 
We can only discuss a subset of the published 
studies, and there are many more. We refer to re-
cent excellent review articles that summarize all 
the available evidence for galectin-3 (19,34,35). 
Also, there is a recent meta-analysis that helps to 
compile the aggregate evidence (36). We discuss 
a few of the most interesting articles.
Lin et al. observed a correlation of galectin-3 
with cardiac extracellular matrix (ECM) turnover 
markers in 106 CHF patients. These correlations 
were still abundant after adjusting for age, sex, 
smoking status and NYHA class (37). 
The prognostic importance of galectin-3 was 
analyzed for the first time in 232 chronic HF 
patients with systolic dysfunction and severe 
HF (38). These patients, by Lok et al., were 
also studied in a follow up study, with 9-years 
follow-up. After adjustment for several estab-
lished risk factors, galectin-3 remained an in-
dependent prognostic marker for long-term 
all-cause mortality (Figure 2B) (23,39). Next to 
this, they observed an independent relation-
ship between galectin-3 and left ventricular 
remodeling determined by serial echocardiog-
raphy (24). The latter finding strengthened the 
hypothesis that galectin-3 is involved in cardiac 
remodeling. The HF-ACTION investigators did 
not only measure ST2 as described above, but 
also measured galectin-3 in a sub-cohort of 
895 patients (40). Galectin-3 levels at baseline 
were related to the primary outcome of the 
study, all-cause mortality or rehospitalization. 
Patients with both elevated levels of galectin-3 
and NT-proBNP had a two times higher risk for 
all-cause death or rehospitalization. Galectin-3 
eJIFCC2016Vol27No3pp238-252
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alone lost its predictive value after adjustment 
for NT-proBNP for the composite endpoint, car-
diovascular death or cardiovascular hospitaliza-
tion. In a more recent analysis of the same study, 
mortality was divided in death due to heart 
failure and sudden cardiac death (SCD), and it 
was shown that galectin-3 had no incremental 
value on top of clinical factors and NT-proBNP 
to predict death due to heart failure, while it did 
add incremental value for the prediction of SCD 
(41). The low baseline levels of galectin-3 in this 
cohort could possibly explain this. 
In the CORONA trial (42), after a median follow-
up of 33 months, galectin-3 univariably pre-
dicted the composite endpoint of cardiovascu-
lar death, nonfatal myocardial infarction and 
stroke, but after adjustment for NT-proBNP this 
was no longer statistically significant. In an ad-
ditional analysis it was shown that, seemingly 
paradoxically, patients with low galectin-3 levels 
may benefit from statin therapy (43). However, 
in the Val-HeFT trial, originally designed to 
evaluate the efficacy of valsartan in chronic 
systolic HF patients, galectin-3 remained sig-
nificantly associated with mortality and HF 
hospitalization, also after addition of both eGFR 
and NT-proBNP to the model (44). The same re-
sults were reported in a smaller trial comprising 
of 133 CHF patients (45). Galectin-3 seems to 
be more influenced by kidney function (46,47) 
than ST2, and it has been shown that elevated 
galectin-3 levels precede and predict renal in-
sufficiency (48). 
In a head-to-head comparison of ST2 and ga-
lectin-3 in 876 ambulatory patients, both ST2 
and galectin-3 were associated with an in-
creased risk for all-cause mortality but ST2 was 
only associated with cardiovascular mortal-
ity. Galectin-3 did not significantly improve the 
performance for prediction of mortality when 
added to a (extensive) base model. The authors 
discussed that the absence of prognostic value 
of galectin-3 in this study may be explained by 
the observation that galectin-3 might confer 
stronger prognostic information in early disease 
as compared to progressed disease (49).
Finally, a recent meta-analysis by Chen et al. 
(36) investigated the relationship between ga-
lectin-3 and all-cause mortality in 8,419 par-
ticipants enrolled in 9 studies, with a follow up 
A. Hazard ratio for all-cause mortality based on groups defined by NT-proBNP and ST2, compared with a reference group 
with low NT-proBNP and low ST2. P values are for change relative to reference group; Figure adapted from Felker et al (26).













Figure 2A,B sST2 and Galectin-3 combined with NT-proBNP in Chronic Heart Failure
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period ranging from 1 to 8.7 years. After correc-
tion for well-established risk factors, including 
in all studies at least age, creatinine (or eGFR) 
and BNP (or NTproBNP), galectin-3 was shown 
to have an independent predictive value for 
mortality in chronic HF.
3. ACUTE HEART FAILURE
Acute HF (AHF) is a main cause of hospitaliza-
tions for people over the age of 65 in the west-
ern world (50) and a leading cause of mortality. 
Dyspnea is the most common symptom of AHF 
patients who are presented at the emergency 
department (ED) (51). Usually a first assess-
ment of AHF patients occurs at the ED, which 
commonly consists of clinical parameters that 
are easy to obtain, such as medical history, use 
of drugs, signs and symptoms of heart failure, 
ECG, chest X-ray and laboratory assessment. 
Currently, biomarker assessment including 
BNP or NT-proBNP and hs-Troponin is com-
monly part of this work up. However, despite 
all these parameters, it has been reported that 
nearly half of the HF hospitalizations were un-
necessary in retrospect (52). This highlights that 
there is room for improvement. Hospitalization 
for AHF is a crucial moment in a patients course 
with the diagnosis, it is estimated that risk for 
death by 1 year is as high as 30% following dis-
charge, with rehospitalization rates exceeding 
50% (53).
3.1. ST2
The first study of ST2 measurement in patients 
with suspected or proven AHF was in the Pro-
BNP Investigation of Dyspnea in the Emergency 
Department (PRIDE) study (54). In 593 patients 
admitted to the emergency department with 
acute dyspnea ST2 was measured. ST2 levels 
were significantly higher in patients with AHF 
than patients with non-HF dyspnea and the like-
lihood for HF diagnosis was greater in patients 
in the highest deciles of ST2. The sensitivity to 
correctly diagnose AHF was significantly better 
for NT-proBNP than for ST2. ST2 concentrations 
predicted 1-year mortality in both patients with 
and without HF, where ST2 showed additive 
prognostic value on top of NT-proBNP (Figure 
3A). In a sub-study of PRIDE in 139 subjects 
conducted by Shah et al. (55) ST2 concentra-
tions were associated with higher LV end-sys-
tolic dimensions and volumes, lower LV ejec-
tion fraction, lower right ventricular fractional 
area change, larger RV systolic pressure and 
hypokinesia. They also demonstrated that ST2 
predicted death at 4 years, independent from 
other traditional clinical, biochemical and echo-
cardiographic risk markers. 
Friões et al. (56) divided AHF patients into 
HFpEF and HFrEF patients, and reported that 
NT-proBNP predicted all-cause mortality or 
readmission at 6 month for both types of pa-
tients. Interestingly, ST2 was reported to be a 
significant marker for prognosis in HFrEF pa-
tients, but not so in HFpEF patients. However, in 
a pooled analysis of three cohorts from Boston, 
Massachusetts, Linz, Austria and Murcia, Spain, 
data were available for 447 patients with AHF. 
They found equally strong prognostic value of 
ST2 irrespective of LVEF (57). The data suggest 
that different pathways for the establishment 
and progression of HF are present, and bio-
markers might help to characterize between 
these phenotypes. 
3.2. Galectin-3
As for ST2, galectin-3 was initially evaluated in 
the PRIDE study published by van Kimmenade 
et al. (58). They demonstrated that galectin-3 
was a better prognostic predictor for 60-day 
mortality compared to NT-proBNP and that 
the combination of both predicted mortal-
ity even better (Figure 3B). This finding was 
strengthened by the comparable observations 
in the Coordinating study evaluating Outcomes 
of Advising and Counseling in Heart Failure 
eJIFCC2016Vol27No3pp238-252
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(COACH) study that enrolled 592 AHF patients 
at discharge (59). In the COACH study galec-
tin-3 seemed to have particularly strong pre-
dictive value in patients with HFpEF, compared 
to patients with HFrEF (59). This finding was 
validated in a PRIDE sub-study which included 
echocardiographic data showing significant re-
lations between galectin-3 and diastolic echo 
parameters. Galectin-3 was significantly corre-
lated with parameters of diastolic function such 
as E/E’ (60). Another large HFpEF cohort com-
prising 419 patients admitted with AHF, demon-
strated the same predictive value of galectin-3 
in patients with HFpEF. Galectin-3 emerged as 
an independent predictor of unfavorable out-
come (mortality and HF hospitalizations), and 
addition of galectin-3 to base models increased 
c-statistics and yielded significant reclassifica-
tion indices. The particularly strong value in 
HFpEF is promising, as currently, the diagnosis 
and therapy of HFpEF are difficult and further 
insight in possible mechanism are needed (59).
Further, Meijers et al. showed that the predic-
tive value of galectin-3 is particularly useful 
for short-term outcomes. Elevated galectin-3 
was strongly associated with near-term re-
hospitalization at 30, 60, 90 and 120 days in 
a pooled analysis comprising three AHF stud-
ies (PRIDE, COACH and the Maryland-study 
(UMD-H23258), totaling 902 AHF patients 
(61). In this study, galectin-3 showed numeri-
cally very high and statistically very strong re-
classification indices. 
Another large study focusing on short-term 
outcome of 603 patients presenting with acute 
dyspnea in the emergency department showed 
that galectin-3 was a strong predictor of 90-day 
outcome. However, in a multivariable model it 
lost its predictive value (62). 
Finally, while most studies report on identifica-
tion of high-risk patients, Meijers et al. recent-
ly assessed whether biomarkers could be used 
for low-risk prediction in AHF patients. Out 
of a large panel of biomarkers galectin-3 was 
the only biomarker able to predict low-risk for 
all cause mortality and/or HF rehospitaliza-
tion adjusted for multiple variables including 
NT-proBNP (63). 
A. Mortality rates at 1 year as a function of ST2 and NT-proBNP concentrations among patients with acute HF (n = 208) (54). 







Figure 3A,B sST2 and Galectin-3 combined with NT-proBNP in Acute Heart Failure
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4. INCIDENT HEART FAILURE
Despite significant progress in the treatment 
of heart failure (HF), the incidence and preva-
lence of this diagnosis are rising. This trend is 
expected to continue and is attributed primar-
ily to the increasing proportion of elderly in 
the population, improved care of acute heart 
diseases resulting in improved patient surviv-
al, and increasing prevalence of cardiovascu-
lar risk factors such as obesity and diabetes. 
Biomarkers might identify subjects at risk for 
incident HF.
4.1. ST2
Four community-based cohorts have exam-
ined ST2 concentrations at baseline namely the 
FINRISK97 population cohort (64), Framingham 
Heart Study (65), the Dallas Heart Study (66), 
and the Cardiovascular Health Study (67).
Hughes et al. investigated the predictive value 
of ST2 in a large Finnish general population 
study (N=8444). In this cohort of healthy indi-
viduals, ST2 adds little predictive information 
beyond standard risk markers for cardiovascular 
endpoints, such as MACE, CVD and stroke, and 
is of marginal benefit to all-cause mortality pre-
diction in a general population of healthy par-
ticipants. ST2 also failed to improve prediction 
for heart failure either as an individual marker 
following adjustment for Framingham risk fac-
tors or in addition to the established cardiac 
marker NT-proBNP and/or eGFR. 
In contrast, in 3,428 Framingham participants 
followed for approximately 11 years, sST2 was 
associated with both incident heart failure and 
all-cause mortality. Subjects in the highest quar-
tile of sST2 had a 2.5-fold increased risk of inci-
dent heart failure compared with those in the 
lowest quartile. 
ST2 was also measured (using a less sensitive re-
search-use-only method) in 3,294 participants 
of the Dallas Heart Study, who were followed 
for a median of 8 years. In this analysis, most 
subjects did not have measurable sST2. In con-
trast to data from other cohorts, ST2 concentra-
tions were not associated with most traditional 
cardiovascular risk factors. Since the assay used 
in the Dallas Heart Study differs so strongly from 
the ones used in other studies, it is difficult to 
compare the studies. 
Most recently, ST2 concentrations were mea-
sured in 3,915 participants of the Cardiovascular 
Health Study free of heart failure. During a me-
dian follow-up of 15 years, ST2 concentrations 
at baseline predicted incident cardiovascu-
lar events in multivariable-adjusted analyses. 
Specifically, participants in the upper quintile of 
sST2 had a greater risk of heart failure and car-
diovascular death compared with participants 
in the lowest quintile.
4.2. Galectin-3
Six community-based cohorts have exam-
ined galectin-3 concentrations at baseline, 
namely the Framingham Heart Study (68), the 
Physician Health study (case control) (69), the 
PREVEND study (70), FINRISK97 population co-
hort (71), the Rancho Bernado study (72), and 
the Cardiovascular Health Study (67).
In the Framingham (offspring) study, galectin-3 
levels were available in 3,353 participants, who 
were observed during a mean follow-up of 11 
years. Galectin-3 was a significant predictor of HF 
risk, also after multivariable adjustment. This ob-
servation was validated in the Physicians’ Health 
Study, which used a case-control design, describ-
ing 462 cases and 462 controls. After adjusting 
for clinical variables there was a significant rela-
tion between galectin-3 and new onset HF.
The Physicians’ Health Study validated the 
Framingham findings in a nested case control de-
sign, including approximately 900 subjects. After 
adjusting for BMI, diabetes, AF, hypertension, 
CRP, alcohol and smoking there was a significant 
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relation between galectin-3 and new onset HF, 
with or and without prior CHD.
In the PREVEND (PREvention of Vascular and 
End stage ReNal Disease) study, a total of 8,569 
subjects were followed during a median follow-
up of 13 years. Galectin-3 emerged as a predic-
tor of new onset HF in subjects with high CV risk 
compared to subjects with low CV risk.
The same cohort as described earlier, the gen-
eral population-based FINRISK 1997 cohort 
evaluated the usefulness of galectin-3. They ob-
served that galectin-3 levels were predictive for 
future cardiovascular events, also after adjust-
ment for gender. However, the reclassification 
indices were modestly improved. 
In an elderly cohort (mean age 70 years), the 
Rancho Bernardo Study, baseline galectin-3 
levels were independently associated with all-
cause and CVD mortality. These elderly subjects 
had no known CVD prior to the study participa-
tion. Addition of galectin-3 to the model result-
ed in significant reclassification indices. 
Both ST2 and galectin-3 was measured in the 
Cardiovascular Health Study. Comparable re-
sults for both biomarkers were observed and 
subjects in the upper quintile of galectin-3 level 
had a greater risk of heart failure and cardio-
vascular death compared to participants in the 
lowest quintile.
5. THERAPEUTIC GUIDANCE
Serial ST2 sampling over time during aggres-
sive HF therapy seems to be a strong prognostic 
indicator for future outcomes (73). Especially 
adjustment of β-blocker dose might be associ-
ated with changes in ST2 levels (74). In a post 
hoc analysis from the PROTECT trial (75), it was 
observed that β-blocker therapy exerted ben-
eficial effects across the complete study popu-
lation. Patients with high ST2 levels and a low 
dose of β-blocker were at the highest risk for 
cardiovascular events. However, up-titration of 
beta-blocker therapy nowadays is part of the 
standard clinical care so it is questionable if we 
would need a biomarker-guided treatment. 
Next to an association with β-blockers an asso-
ciation for both biomarkers with mineralocor-
ticoid receptor antagonists (MRAs) is present. 
Recent experimental data showed that MRA 
treatment after MI strongly reduced both galec-
tin-3 and ST2 expression in the myocardium and 
improved LVEF (76). Aldosterone might play a 
role as mediator of the pro-fibrotic effects of ga-
lectin-3. However in clinical studies (77,78) no 
evidence of the interaction between galectin-3 
and MRA treatment were observed. Therefore, 
it remains unclear whether we should use bio-
marker-guided therapy in the future. 
6. TARGETED THERAPY 
Unraveling the pathophysiological mechanism 
of both biomarkers could be of significant im-
portance. As already described and proven 
in experimental studies, galectin-3 inhibitors, 
such as complex carbohydrates, attenuate the 
cardiac remodeling processes and reduce fi-
brosis formation after different cardiac stress-
ors (79,80). These inhibitors also resulted in 
improved function parameters as fractional 
shortening. Galectin-3 has the potential as a 
new modifiable risk factor in HF patients and it 
would be very interesting to monitor galectin-3 
levels pre and post anti-galectin-3 treatment 
(81). No such data exist for ST2. 
7. CONCLUSION –  
READY FOR PRIME TIME?
We have provided an overview of the poten-
tial value of ST2 and galectin-3 in chronic heart 
failure, acute heart failure and incident heart 
failure. Both ST2 and galectin-3 show prognos-
tic value in mostly all patients with chronic and 
acute HF, on top of natriuretic peptides. 
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As clearly shown in all figures, both sST2 and ga-
lectin-3 predict outcome more accurately when 
combined with NT-proBNP. These consistent 
findings may pave the road for the implementa-
tion of sST2 and galectin-3 in chronic heart fail-
ure algorithms. Strategies that combine multi-
ple biomarkers may ultimately prove beneficial 
in guiding HF therapy in the future. 
This is also true for AHF patients, but in this set-
ting even serial measurements of both galec-
tin-3 and sST2 would provide further insights 
in patient management strategies, for example 
at discharge and 3-6 months later during the 
“chronic” state of the disease.
When considering risk assessment, there is no 
urgent need for additional prognostic tests. 
Current models already very accurately predict 
prognosis in our HF patients, and addition of 
more factors show modest improvement of the 
models. We do not need biomarkers to tell us to 
take medication that is part of evidence-based 
therapy, which we should start and up titrate in 
all HF patients. 
So, the most challenging task will be to de-
sign, fund and launch prospective studies that 
incorporate biomarker based treatment algo-
rithms. Such studies will provide definite data 
as to whether it is useful and economical to 
order (expensive) biomarker tests on the long 
run. Such studies should test biomarker spe-
cific or targeted therapies, not the state of the 
art medication that is part of daily care. Only 
in this manner, HF management will move for-
ward towards more personalized approaches, 
which might lead to the use of multiple bio-
markers. Learning the most efficient ways to 
exploit them to assess and risk stratify patients 
should be the goal of the upcoming years. 
Testing algorithms including ST2 and or galec-
tin-3 could be a first step towards more per-
sonalized medicine.
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